Bibliography
- ARRANG JM, GARBARG M, SCHWARTZ JC: Autoinhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature (1983) 302:832-837.
- LOVENBERG TW, ROLAND BL, WILSON SJ et al.: Cloning and functional expression of the human histamine H3 receptor. Mol. Pharmacol. (1999) 55:1101-1107.
- CELANIRE S, WIJTMANS M, TALAGA P, LEURS R, DE ESCH IJP: Histamine H3 receptor antagonists reach out for the clinic. Drug Disc. Today (2005) 10:1613-1627.
- HANCOCK AA, BRUNE ME: Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists. Expert Opin. Investig. Drugs (2005) 14:223-241.
- LEURS R, BAKKER RA, TIMMMERMAN H, DE ESCH IJP: The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat. Rev. Drug Disc. (2005) 4:107-120.
- BONGERS G, BAKKER RA, LEURS R: Molecular aspects of the histamine H3 receptor. Bio. Pharmacol. (2007) 73:1195-1204.
- ASLANIAN R, SHIH N-Y: Recent progress in histamine H3 receptor chemistry. Ann. Reports Med. Chem. (2004) 39:57-66.
- VOHORA D: Histamine-selective H3 receptor ligands and cognitive functions: an overview. IDrugs (2004) 7:667-673.
- PASSANI MB, LIN J-S, HANCOCK A, CROCHET S, BLANDINA P: The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol. Sci. (2004) 25:618-625.
- HANCOCK AA, FOX GB: Perspectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin. Investig. Drugs (2004) 13:1237-1248.
- HOWARD HR: Agents for attention-deficit hyperactivity disorder - an update. Expert Opin. Ther. Patents (2004) 14:983-1008.
- HANCOCK AA: H3 receptor antagonists/inverse agonists as anti-obesity agents. Curr. Opin. Investig. Drugs (2003) 4(10):1190-1197.
- STARK H: Recent advances in histamine H3/H4 receptor ligands. Expert Opin. Therap. Patents (2003) 13:851-865.
- HAAS H, PANULA P: The role of histamine and the tuberomamillary nucleus in the nervous system. Nat. Rev. Neurosci. (2003) 4:121-130.
- SCHWARTZ JC, ARRANG JM, GARBARG M, POLLARD H, RUAT M: Histaminergic transmission in the mammalian brain. Physiol. Rev. (1991) 71:1-51.
- BAKKER RA: Histamine H3-receptor isoforms. Inflammation Res. (2004) 53:509-516.
- ESBENSHADE TA, KRUEGER KM, YAO BB et al.: Differences in pharmacological properties of histamine H3 receptor agonists and antagonists revealed at two human H3 receptor isoforms. Inflammation Res. (2006) 55(Suppl. 1):S45-S46.
- MARTINEZ-MIR MI, POLLARD H, MOREAU J et al.: Three histamine receptors (H1, H2, and H3) visualized in the brain of human and non-human primates. Brain Res. (1990) 526:322-327.
- SCHLICKER E, KATHMANN M: Modulation of in vitro neurotransmission in the CNS and in the retina via H3 heteroreceptors. In: The Histamine H3 Receptor; a Target for New Drugs. Leurs R, Timmerman H (Eds), Elsevier (1998):13-26.
- BERTACCINI G, CORUZZI G, POLI E: Functional role of histamine H3 receptors in peripheral tissues. Pharmacochem. Library (1998) 30:59-111.
- BERLIN M, TING PC, VACCARO WD et al.: Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists. Bioorg. Med. Chem. Lett. (2006) 16:989-994.
- ASLANIAN RA, ZHU X, TOM WC et al.: Benzimidazole-substituted (3-phenyoxypropyl)amines as histamine H3 antagonists. 232nd American Chemical Society National Meeting. San Fransisco, USA (2006):MEDI-501.
- ESBENSHADE TA, FOX GB, KRUEGER KM et al.: Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. J. Pharm. Exp. Ther. (2005) 313:165-175.
- FOX GB, ESBENSHADE TA, PAN JB et al.: Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J. Pharm. Exp. Ther. (2005) 313:176-190.
- COWART M, FAGHIH R, CURTIS MP et al.: 4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention. J. Med. Chem. (2005) 48:38-55.
- COWART M, PRATT JK, STEWART AO, BENNANI YL, ESBENSHADE TA, HANCOCK AA: A new class of potent non-imidazole H3 antagonists: 2-aminoethylbenzofurans. Bioorg. Med. Chem. Lett. (2004) 14:689-693.
- LIGNEAU X, PERRIN D, LANDAIS L et al.: BF2.649 [1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. J. Pharmacol. Exp. Ther. (2007) 320:365-375.
- LIGNEAU X, LANDAIS L, PERRIN D et al.: Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Bio. Pharmacol. (2007) 73:1215-1224.
- COOPER I, ABBERLEY L, BRIGGS M et al.: Novel potent H3 antagonists: therapeutics for the treatment of dementia including Alzheimer's disease. The 19th International Symposium in Medicinal Chemistry (Part IV). Istanbul, Turkey (2006):P247.
- LIU H, ALTENBACH RJ, MILLER TR, ESBENSHADE TA, HANCOCK AA, COWART M: Design, synthesis, and structure-activity relationship of novel non-imidazole histamine H3 antagonists. 230th American Chemical Society National Meeting. Washington, USA (2005):MEDI-103.
- ALTENBACH RJ, LIU H, ESBENSHADE TA, FOX GB, HANCOCK AA, COWART M: Bicyclic heteroaromatic histamine H3 antagonists: synthesis, potency, and in vivo profiles of analogs optimized for drug-likeness. 230th American Chemical Society National Meeting. Washington, USA (2005):MEDI-102.
- HOWARD HR: Fused thiazole derivatives having affinity for the histamine H3 receptor. Expert Opin. Ther. Patents (2007) 17:129-131.
- MEDHURST AD, ATKINS AR, BERESFORD IJ et al.: GSK189254 – a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J. Pharmacol. Exp. Ther., JPET Fast Forward. Published on February 27, 2007 as DOI:10.1124/jpet.107.120311.
- COWART M, SUN M, ZHAO C et al.: A new family of histamine H3 receptor antagonists based on a natural product: discovery, development of SAR and properties of the series. European Histamine Research Society - 35th Annual Meeting (Part I). Delphi, Greece (2006):O-31.
- MEDHURST AD, BRIGGS MA, BRUTON G et al.: Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats. Bio. Pharmacol. (2007) 73:1182-1194.
- PARMENTIER R, ANACLET C, GUHENNEC C et al.: The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Bio. Pharmacol. (2007) 73:1157-1171.
- PASSANI MB, GIANNONI P, BUCHERELLI C, BALDI E, BLANDINA P: Histamine in the brain: beyond sleep and memory. Bio. Pharmacol. (2007) 73:1113-1122.
- PAN JB, YAO BB, MILLER TR et al.: Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121. Life Sci. (2006) 79:1366-1379.
- TOKITA S, TAKAHASHI K, KOTANI H: Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. J. Pharmacol. Sci. (2006) 101:12-18.
- HANCOCK AA, BITNER RS, KRUEGER KM et al.: Distinctions and contradistinctions between antiobesity histamine H3 receptor (H3R) antagonists compared to cognition-enhancing H3 receptor antagonists. Inflammation Res. (2006) 55(Suppl. 1):S42-S44.
- YOSHIMOTO R, MIYAMOTO Y, SHIMAMURA K et al.: Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc. Natl. Acad. Sci. USA (2006) 103:13866-13871.
- NORMAN P: A H3 antagonist for treating allergic rhinitis: a development candidate? Expert Opin. Ther. Patents (2007) 17(4):449-452.
- FOX GB, PAN JB, RADEK RJ et al.: Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J. Pharm. Exp. Ther. (2003) 305:897-908.
- ESBENSHADE TA, FOX GB, KRUEGER KM et al.: Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. Biochem. Pharmacol. (2004) 68:933-945.
Patents
- BANYU PHARM. CO., LTD.: WO2006059778 (2006).
- BANYU PHARM. CO., LTD.: WO2005077953 (2005).
- BANYU PHARM. CO., LTD.: WO2006129826 (2006).
- BANYU PHARM. CO., LTD.: WO2005115993 (2005).
- BANYU PHARM. CO., LTD.: WO2005077905 (2005).
- BANYU PHARM. CO., LTD.: WO2006085692 (2006).
- BANYU PHARM. CO., LTD.: WO2007004735 (2007).
- SCHERING CORP.: WO2006078775 (2006).
- ATHERSYS, INC.: WO2006004937 (2006).
- ABBOTT LAB.: WO2002074758 (2002).
- ABBOTT LAB.: WO2004101559 (2004).
- ABBOTT LAB.: WO2004043458 (2004).
- WARNER-LAMBERT CO. LLC: WO2005108384 (2005).
- SANOFI-AVENTIS: WO2005037810 (2005).
- UCB SA: WO2006103045 (2006).
- UCB SA: WO2006103057 (2006).
- BIOPROJECT: WO2006117609 (2006).
- PFIZER PRODUCTS, INC.: WO2006136924 (2006).
- JOHNSON & JOHNSON: WO2002012214 (2002).
- LES LABORATOIRES SERVIER: WO2005089747 (2005).
- PFIZER PRODUCTS, INC.: WO2006046131 (2006).
- HOFFMANN-LA ROCHE AG: WO2005117865 (2005).
- HOFFMANN-LA ROCHE AG: US2006009449 (2006).
- PFIZER LMT: EP1595881 (2005); WO2005111036 (2005).
- JOHNSON & JOHNSON: WO2006138714 (2006).
- JOHNSON & JOHNSON: WO2006066197 (2006).
- JOHNSON & JOHNSON: WO2006138604 (2006).
- PFIZER, INC.: US2005282811 (2005).
- PFIZER, INC.: US2006047114 (2006).
- BIOPROJECT: WO2006117611 (2006).
- FERRER INT. SA: WO2006084833 (2006).
- PFIZER, INC.: US2005245543 (2005).
- PFIZER, INC.: US2006019998 (2006).
- GLAXO LTD.: WO2006040192 (2006).
- GLAXO LTD.: WO2006029906 (2006).
- NOVO NORDISK A/S: WO2005009976 (2005).
- BANYU PHARM. CO., LTD.: WO2005007644 (2005).
- ABBOTT LAB.: WO2006132914 (2006).
- HOFFMANN-LA ROCHE AG: WO2006063718 (2006).
- BANYU PHARM. CO., LTD.: WO2005028438 (2005).
- LES LABORATOIRES SERVIER: WO2006120349 (2006).
- LES LABORATOIRES SERVIER: WO2006120348 (2006).
- PFIZER, INC.: US2006014733 (2006).
- GLAXO LTD.: WO2005014571 (2005).
- JOHNSON & JOHNSON: US2005222151 (2005).
- JOHNSON & JOHNSON: US2005222129 (2005).
- SCHERING CORP.: WO2007002057 (2007).
- SCHERING CORP.: WO2007001975 (2007).
- GLAXO LTD.: WO2006125665 (2006).
- GLAXO LTD.: US2006293298 (2006).
- ELI LILLY & CO.: WO2006044228 (2006).
- ELI LILLY & CO.: WO2006023462 (2006).
- ELI LILLY & CO.: WO2006019833 (2006).
- ELI LILLY & CO.: WO2005121080 (2005).
- ELI LILLY & CO.: WO2005097740 (2005).
- ELI LILLY & CO.: WO2005082893 (2005).
- ELI LILLY & CO.: WO2006107661 (2006).
- ELI LILLY & CO.: WO2006101808 (2006).
- ABBOTT LAB.: US2005272728 (2005).
- ABBOTT LAB.: US2005272736 (2005).
- ABBOTT LAB.: US2005256309 (2005).
- ABBOTT LAB.: US2005256118 (2005).
- ABBOTT LAB.: US2005256127 (2005).
- HOFFMANN-LA ROCHE AG.: WO2006045416 (2006).
- HOFFMANN-LA ROCHE AG.: WO2006077024 (2006).
- HOFFMANN-LA ROCHE AG.: WO2005123716 (2005).
- PFIZER, INC.: 6US2006069087 (2006).
- GLAXO LTD.: WO2006072596 (2006).
- GLAXO LTD.: WO2005123723 (2005).
- GLAXO LTD.: WO2005097778 (2005).
- GLAXO LTD.: WO2006018260 (2006).
- GLAXO LTD.: WO2005058837 (2005).
- GLAXO LTD.: WO2005087746 (2005).
- GLAXO LTD.: WO2006097691 (2006).
- GLAXO LTD.: WO2006061193 (2006).
- GLAXO LTD.: WO2004056369 (2004).
- BANYU PHARM. CO., LTD.: WO2006028239 (2006).
- SANOFI-SYNTHELABO: WO2005118547 (2005).
- ASTRAZENECA AB.: WO2006014135 (2006).
- ASTRAZENECA AB.: WO2006014136 (2006).
- ASTRAZENECA AB.: WO2006014134 (2006).
- HOFFMANN-LA ROCHE AG.: WO2006058649 (2006).
- PFIZER, INC.: US2005171181 (2005).
- NEUROGEN CORP.: WO2006089076 (2006).
- ATHERSYS, INC.: WO2006071750 (2006).
- KYOWA HAKKO KOGYO CO., LTD: WO2006080519 (2006).
- ABBOTT LAB.: WO2005100377 (2005).
- MERCK & CO., INC.: WO2005097111 (2005).
- MERCK & CO., INC.: WO2006058023 (2006).
- EHIME UNIV, JPN: WO2006041061 (2006).
- BANYU PHARM. CO., LTD.: WO2007032536 (2007).
- GLAXO LTD: WO2006090142 (2006).
Website
- http://www.ferrergrupo.com/ FERRER INT. website. Farmacia/Moléculas en fase de desarrollo (2006).
- http://www.iddb3.com Investigational Drugs database (IDdb), Thomson Current Drugs (2007).
- http://www.gsk.com/investors/pp_pipeline_standard.htm (2007); http://www.gsk.com/investors/reps06/annual-report-2006.pdf Annual Report (2006). Glaxo website.
- http://www.clinicaltrials.gov/ct/show/NCT00387413?order=1
- http://www.clinicaltrials.gov/ct/show/NCT00366080?order=2